

10/578387

Attorney's Docket No. 035784/311263

IN THE UNITED STATES DESIGNATED OFFICE (DO/US)

AP20 Rec'd PCT/PTO 02 MAY 2006

In re: Long *et al.*

Attn: DO/US

International Appl. No.: PCT/US2004/037281

International Filing Date: November 4, 2004

For: USE OF ANTAGONIST ANTI-CD40 MONOCLONAL ANTIBODIES FOR TREATMENT OF MULTIPLE MYELOMA

May 2, 2006

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


INFORMATION DISCLOSURE STATEMENT

Sir:

The documents listed on the attached PTO-1449 were cited in the International Search Report of corresponding International Application No. PCT/US2004/037281. A copy of the Search Report is enclosed for the Examiner's convenience. Applicant encloses copies of any cited foreign patent documents and non-patent literature in accordance with 37 CFR 1.98(a)(2). Note that Cite No. 4, EP 1 391 464 A1, is an English equivalent for Cite No. 1, WO 02/088186 A1.

The Examiner may wish to consider the notations on the Search Report itself regarding the relevance of each item. It is requested that the Examiner consider these references and officially make them of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead submitting the listed documents for the sake of full disclosure.

Respectfully submitted,



Leslie T. Henry
Registration No. 45,714


ALSTON & BIRD LLP

Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
Tel Raleigh Office (919) 862-2200
Fax Raleigh Office (919) 862-2260
Customer No. 00826

"Express Mail" Mailing Label Number EV 387075904 US

Date of Deposit: May 2, 2006

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop PCT, Attn: DO/US Commissioner for Patents, Alexandria, VA 22313-1450.


Lynda-Jo Pixley

Substitute for form 1449/PTO (Revised 07/2005) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known		
				Application Number	To Be Assigned	
				Filing Date	Filed Concurrently Herewith	
				First Named Inventor	Long	
				Group Art Unit	035784/311263	
Examiner Name	To Be Assigned					
Sheet	1	of	1	Attorney Docket Number	035784/311263	
U. S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear	
FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
	1	WO 02/088186 A1	11-07-2002	Kirin Beer Kabushiki Kaishai		
	2	WO 02/28904 A2	04-11-2002	Chiron Corporation		
	3	WO 01/83755 A2	11-08-2001	Gemini Science, Inc.		
	4	EP 1 391 464 A1	02-25-2004	Kirin Beer Kabushiki Kaishai		
	5	WO 02/28480 A2	4-11-2002	Chiron Corporation		
OTHER DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				English Language Translation Attached
	6	TAI, Y., <i>et al.</i> , "Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications," <i>Cancer Research</i> , 2004, pp. 2846-2852, Vol. 64(8).				
	7	WENG, WEN-KAI, <i>et al.</i> , "Human Anti-CD40 Antagonistic Antibodies Inhibit the Proliferation of Human B Cell Non-Hodgkin's Lymphoma," <i>Blood</i> , 2001, p. 466a, Vol. 98, No. 11, Part 1, Abstract # 1947.				
Examiner Signature				Date Considered		

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.